Overview
Marta Chierichetti practices in Milan, Italy. Ms. Chierichetti is highly rated in 3 conditions, according to our data. Her top areas of expertise are Primary Lateral Sclerosis, Spinal and Bulbar Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Spinal Muscular Atrophy (SMA).
Her clinical research consists of co-authoring 21 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
- Primary Lateral SclerosisMs. Chierichetti isAdvanced. Learn about Primary Lateral Sclerosis.
- Spinal and Bulbar Muscular AtrophyMs. Chierichetti isAdvanced. Learn about Spinal and Bulbar Muscular Atrophy.
- Experienced
- Charcot-Marie-Tooth DiseaseMs. Chierichetti isExperienced. Learn about Charcot-Marie-Tooth Disease.
- Cramp-Fasciculation SyndromeMs. Chierichetti isExperienced. Learn about Cramp-Fasciculation Syndrome.
- Embryonal Tumor with Multilayered RosettesMs. Chierichetti isExperienced. Learn about Embryonal Tumor with Multilayered Rosettes.
- Muscle AtrophyMs. Chierichetti isExperienced. Learn about Muscle Atrophy.
- NeuroblastomaMs. Chierichetti isExperienced. Learn about Neuroblastoma.
- Neurotoxicity SyndromesMs. Chierichetti isExperienced. Learn about Neurotoxicity Syndromes.